Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents.
chronic hepatitis C
cirrhosis
direct antiviral agents
drug use
healthcare resources
Journal
Journal of viral hepatitis
ISSN: 1365-2893
Titre abrégé: J Viral Hepat
Pays: England
ID NLM: 9435672
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
10
09
2020
accepted:
23
01
2021
pubmed:
9
2
2021
medline:
2
10
2021
entrez:
8
2
2021
Statut:
ppublish
Résumé
The aim of this study was to analyse the impact of treating chronic hepatitis C (CHC) with direct-acting agents (DAA) on the use of healthcare resources. We included all patients treated with DAA for CHC from January 2015 to December 2017 in Catalonia whose medical records from 12 months before to 24 months after treatment were available. Data were obtained from the Catalan Health Surveillance System. A total of 12,199 patients in Catalonia were treated with DAA for CHC. Of these, 11.3% had no-minimal fibrosis (F0-F1), 24.0% had moderate fibrosis (F2), 50.3% had significant fibrosis or cirrhosis (F3-F4), and 14.4% had decompensated cirrhosis. Use of healthcare resources decreased from the pre-treatment period to the post-treatment period for the following: hospital admissions due to complications of cirrhosis, from 0.19 to 0.12 per month per 100 patients (RR 0.57; 95% CI 0.47-0.68); length of hospital stay, from 12.9 to 12.2 days (RR 0.93; 95% CI 0.91-0.94); outpatient visits, from 65.0 to 49.2 (RR 0.75; 95% CI 0.74-0.75); and number of medication containers per patient per month, from 13.9 to 12.5 (RR 0.837; 95% CI 0.835-0.838). However, the number of invoices for antineoplastic treatment increased after DAA treatment, especially for patients with high morbidity or advanced fibrosis stage. In conclusion, a decrease in health resource use was seen in CHC patients treated with DAA, as measured by length of hospital stay, number of admissions due to cirrhosis complications, outpatient visits and overall drug invoicing. However, use of antineoplastic drugs increased significantly, especially in patients with cirrhosis and high morbidity.
Substances chimiques
Antiviral Agents
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
728-738Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol. 2018;69(2):461-511.
Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36(5 Suppl 1):S47-56.
Sarin SK, Kumar M. Natural history of HCV infection. Hepatol Int. 2012;6(4):684-695.
Negro F, Samii K, Rubbia-Brandt L, et al. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. J Med Virol. 2000;60(1):21-27.
Leandro G, Mangia A, Hui J, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130(6):1636-1642.
Thein HH, Yi Q, Dore GJ, Krahn MD. Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS. 2008;22(15):1979-1991.
Alberti A, Pontisso P, Chemello L, et al. The interaction between hepatitis B virus and hepatitis C virus in acute and chronic liver disease. J Hepatol. 1995;22(1 Suppl):38-41.
Borzio M, Dionigi E, Vitale A, et al. Management and prognosis of hepatocellular carcinoma in the elderly: results of an in-field multicenter cohort study. Liver Int. 2017;37(8):1184-1192.
Lingala S, Ghany MG. Natural history of hepatitis C. Gastroenterol Clin North Am. 2015;44(4):717-734.
Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999;42(10):2204-2212.
Cacoub P, Buggisch P, Carrión JA, et al. Direct medical costs associated with the extrahepatic manifestations of hepatitis C infection in Europe. J Viral Hepat. 2018;25(7):811-817.
Cacoub P, Desbois AC, Comarmond C, Saadoun D. Impact of sustained virological response on the extrahepatic manifestations of chronic hepatitis C: a meta-analysis. Gut. 2018;67(11):2025-2034.
Calvaruso V, Craxì A. Why do I treat my patients with mild hepatitis C? Liver Int. 2016;36(Suppl 1):7-12.
Gallach M, Vergara M, da Costa JP, et al. Impact of treatment with direct-acting antivirals on anxiety and depression in chronic hepatitis C. PLoS One. 2018;13(12):e0208112.
Calleja JL, Macias J, Forns X, et al. Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). Gastroenterol Hepatol. 2018;41(9):597-608.
Kwong A, Kim WR, Mannalithara A, Heo NY, Udompap P, Kim D. Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States. Liver Transpl. 2018;24:735-743.
Younossi ZM, Tanaka A, Eguchi Y, Henry L, Beckerman R, Mizokami M. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. J Viral Hepat. 2018;25(8):945-951.
Younossi ZM, Chan HLY, Dan YY, et al. Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. J Viral Hepat. 2018;25(3):228-235.
Spanish Ministry of Health. Plan Estratégico para el Abordaje de la hepatitis C. https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/hepatitisC/PlanEstrategicoHEPATITISC/docs/plan_estrategico_hepatitis_C.pdf
Desai AP, Mohan P, Nokes B, et al. Increasing economic burden in hospitalized patients with cirrhosis: analysis of a national database. Clin Transl Gastroenterol. 2019;10(7):e00062.
Vergara M, Clèries M, Vela E, Bustins M, Miquel M, Campo R. Hospital mortality over time in patients with specific complications of cirrhosis. Liver Int. 2013;33(6):828-833.
Stepanova M, Younossi ZM. Economic burden of hepatitis C infection. Clin Liver Dis. 2017;21(3):579-594.
Dimitrova M, Pavlov K, Mitov K, Genov J, Petrova GI. Chronic hepatitis C-related cirrhosis hospitalization cost analysis in Bulgaria. Front Med. 2017;4:125.
Gordon SC, Pockros PJ, Terrault NA, et al. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology. 2012;56(5):1651-1660.
Dueñas-Espín I, Vela E, Pauws S, et al. Proposals for enhanced health risk assessment and stratification in an integrated care scenario. BMJ Open. 2016;6(4):e010301.
Monterde D, Vela E, Clèries M; Grupo Colaborativo GMA. Adjusted morbidity groups: a new multiple morbidity measurement of use in primary care. Aten Primaria. 2016;48(10):674-682.
Monterde D, Vela E, Clèries M, Garcia-Eroles L, Roca J, Pérez-Sust P. Multimorbidity as a predictor of health service utilization in primary care: a registry-based study of the Catalan population. BMC Fam Pract. 2020;21(1):39.
Collaborators GC. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5(3):245-266.
Miquel M, Clèries M, Vergara M, Vela E. Economic burden of cirrhosis in Catalonia: a population-based analysis. BMJ Open. 2018;8(3):e018012.
Fehily SR, Papaluca T, Thompson AJ. Long-term impact of direct-acting antiviral agent therapy in HCV cirrhosis: critical review. Semin Liver Dis. 2019;39(3):341-353.
Organitzacio Catalana de Trasplantament. Registre de Trasplantament Hepàtic de Catalunya. Informe estadistic. Barcelona:Servei Catala de la Salut. 1984-2017.
Khoury J, Nassar G, Kramsky R, Saadi T. Extrahepatic malignancies after treatment with direct antiviral agents for chronic HCV infection. J Gastrointest Cancer. 2020;51:584-590.
Kim D, Adejumo AC, Yoo ER, et al. Trends in mortality from extrahepatic complications in patients with chronic liver disease, from 2007 through 2017. Gastroenterology. 2019;157(4):1055-1066.e11.
Masarone M, Persico M. Hepatitis C virus infection and non-hepatocellular malignancies in the DAA era: a systematic review and meta-analysis. Liver Int. 2019;39(7):1292-1306.